Diabetes Dialogues | Less is More: The Promise of Weekly Insulin in Type 2 Diabetes
Released On
February 18, 2025
Expires On
February 3, 2026
Media Type
Internet
Completion Time
75 minutes
Specialty
Endocrinology, Primary Care
Topic(s)
Basal Insulin Therapy, Diabetes
This activity is provided by ACOFP and MLI.
This activity is supported by an educational grant from Lilly.
Credit Available
- Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is intended for PCPs and other members of the healthcare team in the U.S. who care for patients with T2D.
Program Overview
Explore how weekly insulin innovations are reshaping T2D treatment through an evidence-based review of ultra-long-acting basal insulin and clinical trial insights. Tailored specifically for primary care physicians (PCPs), a 15-minute pre-work session offers practical strategies for integrating these advances into your practice.
Then dive into the 60-minute course, developed in collaboration with The American College of Osteopathic Family Physicians (ACOFP), to deepen your understanding of innovative insulin therapies for T2D. Through a detailed exploration of cutting-edge clinical practices, this activity provides actionable strategies for seamlessly integrating weekly insulin options into patient care.
Key Topics Include:
- Insights into ultra-long-acting basal insulin for T2D
- Best practices for initiating and managing weekly insulin
- Clinical considerations for optimizing patient outcomes
- Describing the place of novel insulin therapies, including once-weekly basal insulin, in treating T2D
- Developing strategies for initiating, dosing, and titrating once-weekly basal insulin for T2D
- Examining the consequences of delaying initiation and intensification of basal insulin in eligible patients
- Communicating to your patients the advantages of once-weekly basal insulin, considering patient concerns about weight gain and hypoglycemia
Stay ahead in diabetes care with expert-led, accessible, and actionable content. Join now to transform your approach to T2D management!
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the place of novel insulin therapies, including once-weekly basal insulin, in treating T2D
- Develop strategies for initiating, dosing, and titrating once-weekly basal insulin for T2D
- Examine the consequences of delaying initiation and intensification of basal insulin in eligible patients
- Communicate to your patients the advantages of once-weekly basal insulin, considering patient concerns about weight gain and hypoglycemia
Agenda
- Once-Weekly Insulin: Trials, Trends, and Tackling Inertia
- Introduction to Once-Weekly Insulin Formulations
- Clinical Trial Results
- Simplifying Data Interpretation
- Once-Weekly Insulin: A Game Changer in a Crowded Market
- Practices for Initiating and Dosing Once-Weekly Basal Insulin in T2D
- The Promise of Once-Weekly Insulin
- Key Takeaways and Conclusions
- Q&A with Expert Faculty
Faculty
Eda Cengiz, MD, MHS
Bio
Benioff Professor in Children’s Health
Professor of Pediatrics
Director of UCSF Pediatric Diabetes Program
University of California San Francisco
San Francisco, CA, USA
Jay H. Shubrook, DO, FACOFP, FAAFP
Bio
Professor, Diabetologist
Department of Clinical Sciences and Community Health
Touro University California, College of Osteopathic Medicine
Vallejo, CA, USA
Carol Hatch Wysham, MD
Bio
Clinical Professor of Medicine
University of Washington School of Medicine
Medical Manager, Diabetes and Endocrinology Clinic
MultiCare Rockwood Clinic
Spokane, WA, USA
Accreditation Statement
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Osteopathic Physician Continuing Medical Education
The American College of Osteopathic Family Physicians (ACOFP) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
ACOFP designates this enduring activity for a maximum of 1.25 AOA Category 1-A credits and will report continuing medical education (CME) credits commensurate with the physician’s participation in this program.
Allopathic Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
AAFP CME Credit
The AAFP has reviewed Less is More: The Promise of Weekly Insulin in Type 2 Diabetes and deemed it acceptable for up to 1.25 Enduring Materials, Self-Study AAFP Prescribed credit(s). Term of Approval is from 02/18/2025 to 02/03/2026. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Disclosure & Conflict of Interest Policy
ACOFP is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of an ineligible company. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, also adopted by the AOA, ACOFP requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients). Individuals in a position to control the content may include, but are not limited to, planning committee members, authors, faculty, speakers, reviewers, and activity staff.
Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
Eda Cengiz, MD, MHS, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Arecor, Eli Lilly, MannKind, Novo Nordisk, Portal Insulin, Tandem
Planner/Presenter
Jay H. Shubrook, DO, FACOFP, FAAFP, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Abbott, Bayer, Eli Lilly, Madrigal, Novo Nordisk, Sanofi
Other: Member of American Diabetes Association, American College of Diabetology (Chair of the Executive Board), American College of Osteopathic Family Physicians, American Academy of Family Physicians, American Osteopathic Association and the Global NASH Council.
The following relationships have ended within the last 24 months:
Consultant/Advisor: Nevro (ended 6/2023)
Planner/Presenter
Carol Hatch Wysham, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Abbott, Biomea (ended), MannKind, Novo Nordisk
Speaker's Bureau: Eli Lilly, MannKind, Novo Nordisk
Research Support: AbbVie, Bayer, Eli Lilly, Novo Nordisk (all to institution)
Stock Options: Pendulum
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, and ACOFP, the joint provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Instructions for Participation and Credit
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
To submit questions to the presenter please send them to [email protected] and include the course title so we can direct them correctly.
If you have questions regarding your certificate, please contact MLI at [email protected].
For Physicians, if requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
Course Viewing Requirements
Supported Browsers (Desktop/Mobile)
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Contact Information
About This Activity
Medical Learning Institute Inc and ACOFP are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.
If you have questions regarding your certificate, please contact MLI at [email protected].
Copyright© 2025 Medical Learning Institute Inc | All Rights Reserved
